Eli Lilly has invested $40 million（約64億円） in Absci, a biotech startup developing a medication to spur hair growth, as part of a $100 million（約160億円） funding round. The investment reflects pharmaceutical giants' plans to expand beyond weight loss treatments into other aesthetic fields like hair loss and skin care.
Summaries like this, in your inbox every morning.
Sign up free →What happened
Absci announced it raised $100 million（約160億円） in funding led by Eli Lilly, which contributed $40 million（約64億円） in exchange for equity in the publicly traded biotech startup. Absci is developing a medication intended to spur hair growth and potentially treat endometriosis.
Why it matters
Eli Lilly and other pharmaceutical companies behind blockbuster weight loss drugs like Wegovy and Mounjaro have been signaling plans to expand into adjacent aesthetic fields. This investment marks a concrete first step into hair loss treatment, an area where demand could complement their existing franchise.
What to watch
Absci is publicly traded on Nasdaq, so investors can track the company's progress as it develops its hair growth medication. The startup's ability to bring the treatment to market will test whether Big Pharma's aesthetic ambitions translate into commercial success.
No comments yet. Be the first to share your thoughts!
Log in to join the discussion
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime
5 minutes a day. The AI essentials.
200+ sources · Email / LINE / Slack
